Eli Lilly's $1B buyout bet for Protomer brings the 'next frontier' in smart insulin tech under the Big Pharma's wing

Eli Lilly is looking to shore up its future diabetes franchise by putting $1 billion on the table to buy out next-gen biotech Protomer.